Retinitis Pigmentosa Research Advances in 2021

Retinitis Pigmentosa Research Advances in 2021 Recent developments in research on retinitis pigmentosa 1. FDA Approves Spark’s Vision-Restoring Gene Therapy 2. jCyte Stem-Cell Therapy Moving into Phase 3 Clinical Trial for RP 3. ReNeuron’s Stem-Cell Therapy Performs Encouragingly in Phase 2 Clinical Trial 4. Three Companies Are Conducting Clinical Trials for Their Optogenetic Therapies for Advanced RP5 5. AGTC, Janssen/MeiraGTx, and Biogen Conducting XLRP Gene Therapy Clinical Trials 6. Coave Conducting Gene Therapy Clinical Trial for RP (PDE6B Mutations) 7. Nacuity Launches Clinical Trial for Oral Antioxidant Therapy 8. SparingVision Plans Clinical Trial to Evaluate Sight-Saving Protein for RP 9. ProQR Conducting Clinical Trial of Antisense Oligonucleotide for RHO-P23H Mutation StemActiv contains anti-oxidative, anti-inflammatory and anti-apoptotic substances. It optimizes the inner circumstance of the retina, increases the success rate of future therapies. Meanwhile, StemActiv restores RP vision through increasing oxygen and nutrients supply to the optic nerve cells. Here is the link for ordering StemActiv : https://www.restorevisionherbs.com/sh...